SpringWorks Therapeutics Stock Forecast, Price & News

+1.96 (+2.69 %)
(As of 09/17/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume662,182 shs
Average Volume288,686 shs
Market Capitalization$3.67 billion
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive SWTX News and Ratings via Email

Sign-up to receive the latest news and ratings for SpringWorks Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SpringWorks Therapeutics logo

About SpringWorks Therapeutics

SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase 3 clinical trials for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas; Nirogacestat + belantamab mafodotin -blmf, which is in Phase Ib clinical trial for the treatment of relapsed or refractory multiple myeloma (RRMM); and Nirogacestat + ALLO-715 that is in Phase 1 clinical trial for the treatment of RRMM. In addition, it is developing Nirogacestat + teclistamab, which is in clinical stage that targets BCMA and CD3; Nirogacestat + elranatamab; Nirogacestat + PBCAR269A, which is in Phase 1/2a clinical trial for allogeneic BCMA CAR T cell therapy; Mirdametinib that is in Phase 1/2a clinical trial for the treatment of NF1-PN; Mirdametinib + lifirafenib, a combination therapy that is in Phase 1b/2 clinical trial in patients with advanced or refractory solid tumors; and BGB-3245, an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations, which is in Phase I clinical trial. The company has collaborations with BeiGene, Ltd., GlaxoSmithKline LLC, and Allogene to develop combination approaches with nirogacestat and mirdametinib; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology; and clinical trial collaboration agreement with Seagen Inc. SpringWorks Therapeutics, Inc. was founded in 2017 and is headquartered in Stamford, Connecticut.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

2.53 out of 5 stars

Medical Sector

88th out of 1,351 stocks

Biological Products, Except Diagnostic Industry

11th out of 193 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 4.2Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

SpringWorks Therapeutics (NASDAQ:SWTX) Frequently Asked Questions

Is SpringWorks Therapeutics a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for SpringWorks Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SpringWorks Therapeutics stock.
View analyst ratings for SpringWorks Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than SpringWorks Therapeutics?

Wall Street analysts have given SpringWorks Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but SpringWorks Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is SpringWorks Therapeutics' next earnings date?

SpringWorks Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 11th 2021.
View our earnings forecast for SpringWorks Therapeutics

How were SpringWorks Therapeutics' earnings last quarter?

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) released its earnings results on Wednesday, August, 4th. The company reported ($0.97) earnings per share for the quarter, missing analysts' consensus estimates of ($0.69) by $0.28. During the same period in the previous year, the business earned ($0.47) earnings per share.
View SpringWorks Therapeutics' earnings history

How has SpringWorks Therapeutics' stock been impacted by Coronavirus (COVID-19)?

SpringWorks Therapeutics' stock was trading at $33.23 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, SWTX stock has increased by 125.1% and is now trading at $74.80.
View which stocks have been most impacted by COVID-19

What price target have analysts set for SWTX?

4 Wall Street analysts have issued 1 year price targets for SpringWorks Therapeutics' stock. Their forecasts range from $105.00 to $137.00. On average, they anticipate SpringWorks Therapeutics' share price to reach $117.50 in the next year. This suggests a possible upside of 57.1% from the stock's current price.
View analysts' price targets for SpringWorks Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are SpringWorks Therapeutics' key executives?

SpringWorks Therapeutics' management team includes the following people:
  • Mr. Saqib Islam, CEO & Director (Age 51, Pay $946.31k)
  • Mr. Francis I. Perier Jr., M.B.A., Chief Financial Officer (Age 61, Pay $648.96k)
  • Dr. Badreddin Edris Ph.D., Chief Operating Officer (Age 34, Pay $655.2k)
  • Mr. Herschel S. Weinstein J.D., Gen. Counsel & Sec. (Age 65, Pay $568.64k)
  • Mr. Daniel Pichl, Chief People Officer (Age 38, Pay $428.51k)
  • Dr. L. Mary Smith PH.D., Chief Devel. Officer (Age 54, Pay $655.2k)
  • Mr. Michael P. Nofi, Chief Accounting Officer (Age 50)
  • Ms. Kim Diamond, VP of Communications & Investor Relations
  • Dr. Jens Renstrup M.B.A., M.D., Chief Medical Officer (Age 56)
  • Mr. Bhavesh Ashar, Chief Commercial Officer (Age 55)

Who are some of SpringWorks Therapeutics' key competitors?

What other stocks do shareholders of SpringWorks Therapeutics own?

When did SpringWorks Therapeutics IPO?

(SWTX) raised $126 million in an initial public offering (IPO) on Friday, September 13th 2019. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. ​J.P. Morgan, Goldman Sachs and Cowen​ ​ acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is SpringWorks Therapeutics' stock symbol?

SpringWorks Therapeutics trades on the NASDAQ under the ticker symbol "SWTX."

Who are SpringWorks Therapeutics' major shareholders?

SpringWorks Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include FMR LLC (8.08%), Vanguard Group Inc. (5.51%), BlackRock Inc. (5.06%), ArrowMark Colorado Holdings LLC (2.22%), State Street Corp (2.20%) and Victory Capital Management Inc. (1.78%). Company insiders that own SpringWorks Therapeutics stock include Badreddin Edris, Bain Capital Life Sciences Inv, L Mary Smith, Orbimed Advisors Llc, Saqib Islam and Stephen P Squinto.
View institutional ownership trends for SpringWorks Therapeutics

Which institutional investors are selling SpringWorks Therapeutics stock?

SWTX stock was sold by a variety of institutional investors in the last quarter, including Woodline Partners LP, ArrowMark Colorado Holdings LLC, Morgan Stanley, Morgan Stanley, Bessemer Group Inc., Laurion Capital Management LP, Price T Rowe Associates Inc. MD, and TCW Group Inc.. Company insiders that have sold SpringWorks Therapeutics company stock in the last year include Badreddin Edris, Bain Capital Life Sciences Inv, L Mary Smith, Orbimed Advisors Llc, Saqib Islam, and Stephen P Squinto.
View insider buying and selling activity for SpringWorks Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying SpringWorks Therapeutics stock?

SWTX stock was acquired by a variety of institutional investors in the last quarter, including Bank of America Corp DE, Bank of America Corp DE, BlackRock Inc., Vanguard Group Inc., FMR LLC, Jennison Associates LLC, Bank of Montreal Can, and CIBC Asset Management Inc.
View insider buying and selling activity for SpringWorks Therapeutics
or or view top insider-buying stocks.

How do I buy shares of SpringWorks Therapeutics?

Shares of SWTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is SpringWorks Therapeutics' stock price today?

One share of SWTX stock can currently be purchased for approximately $74.80.

How much money does SpringWorks Therapeutics make?

SpringWorks Therapeutics has a market capitalization of $3.67 billion and generates $35 million in revenue each year. The company earns $-45,570,000.00 in net income (profit) each year or ($1.05) on an earnings per share basis.

How many employees does SpringWorks Therapeutics have?

SpringWorks Therapeutics employs 78 workers across the globe.

What is SpringWorks Therapeutics' official website?

The official website for SpringWorks Therapeutics is

Where are SpringWorks Therapeutics' headquarters?

SpringWorks Therapeutics is headquartered at 100 WASHINGTON BOULEVARD, STAMFORD CT, 06902.

How can I contact SpringWorks Therapeutics?

SpringWorks Therapeutics' mailing address is 100 WASHINGTON BOULEVARD, STAMFORD CT, 06902. The company can be reached via phone at 203-883-9490 or via email at [email protected].

This page was last updated on 9/18/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.